Shandong Runze Pharmaceutical Group, the undertaking unit of the National Torch Program, is one of the top 100 pharmaceutical enterprises in China. The registered capital of the company is 568 million yuan and the total assets are 3.6 billion yuan. In 2012, the sales revenue was more than 4 billion yuan and the foreign exchange earned by exports was more than 200 million dollars. The group consists of 2 research and development companies, 5 chemical synthesis and raw material synthesis companies, 4 pharmaceutical production companies, 1 high-end research and development company and 7 commercial companies. Mainly engaged in the research and development, production and sales of penem, cephalosporins, penicillin, anticancer, cardiovascular and other sterile preparations, APIs and intermediates. Our products cover more than 100 varieties of powders, oral preparations, biopharmaceuticals and pharmaceutical intermediates, semi-synthetic antibiotic raw materials, and some of our products fill the domestic gap. Among them, more than 40 scientific research achievements have passed the provincial appraisal, and 8 scientific research projects are domestic original creation, reaching the international leading level.